Showing 7261-7270 of 7612 results for "".
- Valeant Pharmaceuticals to Acquire Obagi Medical Products for Approximately $344 Millionhttps://practicaldermatology.com/news/20130320-valeant_pharmaceuticals_to_acquire_obagi_medical_products_for_approximately_360_million/2459581/Valeant Pharmaceuticals has entered into an agreement to acquire Obagi Medical Products. The transaction values Obagi common stock at approximately $344 million and was unanimously approved by the Obagi Board of Directors. Under terms of the merger agreement, Valeant will commence a tender offer for
- NeoStrata Introduces Line Lift Duohttps://practicaldermatology.com/news/20130314-neostrata_introduces_line_lift_duo/2459589/NeoStrata Company, Inc. launched the SKIN ACTIVE Line Lift featuring Aminofil™, a novel tyrosine amino acid derivative (N-Acetyl Tyrosinamide) that delivers a rapid volumizing effect in the deep skin matrix to visibly reduce deep facial lines and wrinkles. Applied together twice daily, the SKIN ACTI
- Envy Medical Unveils New Acne Systemhttps://practicaldermatology.com/news/20130311-envy_medical_unveils_new_acne_system/2459595/Envy Medical Inc. recently launched the ClarityMD Acne Solution at the American Academy of Dermatology Annual Meeting on March 1 in Miami. The system includes a Deep Pore Cleanser and Clarifying Gel in a two-step system that's clinically proven to significantly heal acne within days, according to th
- Investigational Injectable Found Safe, Effective for Submental Fathttps://practicaldermatology.com/news/20130311-investigational_injectable_found_safe_effective_for_submental_fat/2459596/An investigational injectable drug for the reduction of submental fat called ATX-101 from Kythera Biopharmaceuticals was found both safe and effective in new data presented at the AAD Meeting in Miami. In the open-label Phase IIIb study, interim results three months after the last ATX-101 treatment
- Apremilast Phase III Results Show Efficacy Over Time for Psoriasishttps://practicaldermatology.com/news/20130311-apremilast_phase_iii_results_show_efficacy_over_time_for_psoriasis/2459597/Results from a new Phase III study presented at the AAD Meeting in Miami demonstrate the efficacy of the oral molecule apremilast (Celgene) in psoriasis patients. The ESTEEM 1 study evaluated efficacy and safety in a range of patients, approximately one-third of which was systemic and/or phototherap
- Valeant Launches Acne Scholarship Programhttps://practicaldermatology.com/news/20130311-valeant_launches_acne_scholarship_program/2459598/Valeant Dermatology recently launched a scholarship program entitled, Acanya® I Can Succeed, an initiative that will provide college scholarship money to students who have had acne and have actively tried to address it. The Acanya I Can Succeed Scholarship program will award a total of up to $48,000
- AAD Unveils New App for Diagnosing and Treating Psoriasishttps://practicaldermatology.com/news/20130311-aad_unveils_new_app_for_diagnosing_and_treating_psoriasis/2459599/At its recent annual meeting in Miami, The American Academy of Dermatology introduced a mobile app of evidence-based clinical guidelines for diagnosing and treating psoriasis and psoriatic arthritis. The free app includes a clinical decision tree; reference guide for diagnoses; arthritic diagnostic
- Novan Therapeutics Presents Data for Potential Topical Agent that Reduces Sebum in Acne Patientshttps://practicaldermatology.com/news/20130228-novan_therapeutics_presents_data_for_potential_topical_agent_that_reduces_sebum_in_acne_patients/2459602/Recent in vitro and animal testing data from Novan Therapeutics indicate that the company's drug candidate, SB204, could lead to a topical treatment for acne that reduces oil production in the skin. Dr. Diane Thiboutot, Professor of Dermatology at Penn State Hershey College of Medicine, notes that,
- Alma Lasers to Present New Technologies at AAD Meetinghttps://practicaldermatology.com/news/20130227-alma_lasers_to_present_new_technologies_at_aad_meeting/2459604/Alma Lasers unveiled its two latest technologies, the vShape focused radiofrequency (RF) workstation and the ClearLift. The RF workstation addresses tailored anti-aging treatments for the face, body, and cellulite. The ClearLift is Q-switched technology penetrates deep beneath the skin and decreases
- Brickell Biotech Announces Funding for Development of Novel Dermatology Treatmentshttps://practicaldermatology.com/news/20130226-brickell_biotech_announces_funding_for_development_of_novel_dermatology_treatments/2459608/Brickell Biotech, Inc., a development-stage pharmaceutical company focused on the development of innovative drug therapies for the treatment of skin diseases, announced a $7 million Series B financing round to fund new chemical entities in dermatology for indications including acne, atopic dermatiti